The overexpression of miR-200c led to suppression of TUBB3 and restored the paclitaxel sensitivity in chemotherapy-resistant cancer cell lines (Cochrane et al., 2009, 2010; Cittelly et al., 2012) and in a xenograft tumor model (Cittelly et al., 2012), suggesting the positive role of miR-200-c as therapeutic agents in ovarian cancer treatment. This evidence concerns the gene TUBB3 and ovarian carcinoma.